Price
Target price
€29.20
€29.20
0.000%
-
0.000%
€68.10
23.12.25 / Stuttgart Stock Exchange
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Ultragenyx Pharmaceutical Inc. Stock
There is no change in the price for Ultragenyx Pharmaceutical Inc. today.
We see a rather positive sentiment for Ultragenyx Pharmaceutical Inc. with 20 Buy predictions and 1 Sell predictions.
Based on the current price of 29.2 € the target price of 68 € shows a potential of 132.88% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Ultragenyx Pharmaceutical Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 0.000% | 0.690% | 2.817% | -29.808% | -29.469% | -29.469% | -79.291% |
| Ironwood Pharmaceuticals | -0.740% | -9.459% | -4.965% | -37.383% | -36.190% | -76.716% | -72.653% |
| Novocure Ltd | -2.280% | 7.340% | 8.635% | -61.544% | -61.332% | -84.916% | -91.963% |
| Iovance Biotherapeutics Inc. | -0.280% | 11.832% | 10.644% | -66.564% | -65.306% | -57.442% | -94.118% |
Comments
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at TD Cowen from $86.00 to $75.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Truist Financial Corporation from $100.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx (RARE) Q2 Revenue Up 13%
Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street
